Literature DB >> 19285280

Thrombotic complications after haematopoietic stem cell transplantation: early and late effects.

Dimitrios A Tsakiris1, André Tichelli.   

Abstract

Haematopoietic stem cell transplantation is currently the only curative option for many haematological malignancies, but is characterized by a wide spectrum of complications, including haemostatic changes. Bleeding and thrombotic events occur in the early and late phases after transplantation. In the early phase, thrombotic events have a variable clinical picture and present either as venous thrombosis, mainly at the site of central venous lines, veno-occlusive disease (also known as sinusoid occlusion syndrome) or transplant-associated microangiopathy. The latter two occur in the context of an acute graft-vs-host reaction, which involves various organs including the endothelium. In the late phase, years or decades after transplantation, thrombotic events present either as common venous thromboses or as arterial occlusions because of the development of premature atherosclerosis combined with diabetes, hypertension and dyslipidaemia, all of which are accelerated under the influence of the post-transplant treatment. This chapter will discuss the incidence, possible causative associations and treatment options of early and late thrombotic events after haematopoietic stem cell transplantation.

Entities:  

Mesh:

Year:  2009        PMID: 19285280     DOI: 10.1016/j.beha.2008.12.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  8 in total

Review 1.  Telomeres, atherosclerosis, and the hemothelium: the longer view.

Authors:  Abraham Aviv; Daniel Levy
Journal:  Annu Rev Med       Date:  2011-10-17       Impact factor: 13.739

Review 2.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

3.  Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients.

Authors:  Jorge Labrador; Lucia Lopez-Anglada; Estefania Perez-Lopez; Francisco S Lozano; Lucia Lopez-Corral; Fermin M Sanchez-Guijo; Lourdes Vazquez; Jose Angel Perez Rivera; Francisco Martin-Herrero; Mercedes Sanchez-Barba; Carmen Guerrero; Maria Consuelo del Cañizo; Maria Dolores Caballero; Jesus Fernando San Miguel; Ignacio Alberca; Jose Ramon Gonzalez-Porras
Journal:  Haematologica       Date:  2012-08-16       Impact factor: 9.941

4.  Venous thromboembolism prophylaxis in hematopoietic stem cell transplantation patients: an international web-based survey of healthcare providers.

Authors:  Amer M Zeidan; Jessica Wellman; Patrick M Forde; Javier Bolaños-Meade; Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

5.  Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.

Authors:  Claire Seydoux; Raphael Battegay; Joerg Halter; Dominik Heim; Katharina M Rentsch; Jakob R Passweg; Michael Medinger
Journal:  Bone Marrow Transplant       Date:  2022-03-31       Impact factor: 5.174

6.  Elevated Fasting Plasma Glucose before Liver Transplantation is Associated with Lower Post-Transplant Survival.

Authors:  Emi Katsura; Tatsuki Ichikawa; Naota Taura; Hisamitsu Miyaaki; Satoshi Miuma; Hidetaka Shibata; Takuya Honda; Masaaki Hidaka; Akihiko Soyama; Fuminao Takeshima; Susumu Eguchi; Kazuhiko Nakao
Journal:  Med Sci Monit       Date:  2016-12-02

7.  Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model.

Authors:  Radhika Gangaraju; Yanjun Chen; Lindsey Hageman; Jessica Wu; Liton Francisco; Michelle Kung; Daniel J Weisdorf; Stephen J Forman; Mukta Arora; Saro H Armenian; Smita Bhatia
Journal:  Blood Adv       Date:  2021-10-26

8.  Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial.

Authors:  Claire Seydoux; Michael Medinger; Sabine Gerull; Joerg Halter; Dominik Heim; Yves Chalandon; Stavroula Masouridi Levrat; Urs Schanz; Gayathri Nair; Marc Ansari; Patrick Simon; Jakob R Passweg; Nathan Cantoni
Journal:  Ann Hematol       Date:  2020-10-23       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.